TGTX Historical Income Statement

TGTX Stock

USD 35.09 0.29 0.83%

Historical analysis of TG Therapeutics income statement accounts such as Other Operating Expenses of 223.7 M, Operating Income of 21.7 M, EBIT of 21.7 M or Research Development of 45.7 M can show how well TG Therapeutics performed in making a profits. Evaluating TG Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of TG Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining TG Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether TG Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in TG Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy TGTX Stock please use our How to Invest in TG Therapeutics guide.

About TGTX Income Statement Analysis

TG Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to TG Therapeutics shareholders. The income statement also shows TGTX investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

TG Therapeutics Income Statement Chart

At this time, TG Therapeutics' Net Income is fairly stable compared to the past year. Cost Of Revenue is likely to rise to about 22 M in 2024, whereas Research Development is likely to drop slightly above 45.7 M in 2024.

Depreciation And Amortization Other Operating Expenses Research Development Total Operating Expenses Selling General Administrative Selling And Marketing Expenses

Depreciation And Amortization

The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of TG Therapeutics. It is also known as TG Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from TG Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into TG Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in TG Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy TGTX Stock please use our How to Invest in TG Therapeutics guide.At this time, TG Therapeutics' Net Income is fairly stable compared to the past year. Cost Of Revenue is likely to rise to about 22 M in 2024, whereas Research Development is likely to drop slightly above 45.7 M in 2024.

TG Therapeutics income statement Correlations

	Depreciation And Amortization	Interest Expense	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Cost Of Revenue	Selling General Administrative	Minority Interest	Selling And Marketing Expenses	Net Income From Continuing Ops	Non Operating Income Net Other	Interest Income	Net Interest Income	Reconciled Depreciation
Depreciation And Amortization		0.52	0.17	0.17	0.51	-0.36	-0.37	0.54	-0.36	0.51	-0.38	-0.6	-0.39	0.71	-0.36	-0.02	-0.15	-0.08	-0.38	0.05	0.72	-0.56	0.6
Interest Expense	0.52		0.78	0.78	0.68	-0.07	-0.07	0.3	-0.06	0.65	-0.1	-0.96	-0.11	0.44	-0.32	0.19	-0.23	-0.25	-0.09	0.14	0.93	-0.99	0.91
Total Revenue	0.17	0.78		1.0	0.34	0.43	0.42	-0.1	0.42	0.3	0.4	-0.69	0.39	-0.13	-0.08	0.19	-0.04	-0.18	0.4	0.02	0.58	-0.74	0.47
Gross Profit	0.17	0.78	1.0		0.34	0.43	0.42	-0.1	0.42	0.3	0.4	-0.69	0.4	-0.13	-0.08	0.19	-0.04	-0.18	0.4	0.02	0.58	-0.74	0.47
Other Operating Expenses	0.51	0.68	0.34	0.34		-0.7	-0.71	0.86	-0.71	1.0	-0.72	-0.76	-0.73	0.73	-0.23	0.08	-0.45	-0.37	-0.72	-0.14	0.84	-0.71	0.74
Operating Income	-0.36	-0.07	0.43	0.43	-0.7		1.0	-0.9	1.0	-0.74	1.0	0.21	1.0	-0.8	0.17	0.07	0.41	0.22	1.0	0.15	-0.37	0.12	-0.36
Ebit	-0.37	-0.07	0.42	0.42	-0.71	1.0		-0.9	1.0	-0.74	1.0	0.21	1.0	-0.8	0.16	0.06	0.4	0.22	1.0	0.16	-0.37	0.12	-0.36
Research Development	0.54	0.3	-0.1	-0.1	0.86	-0.9	-0.9		-0.9	0.87	-0.9	-0.43	-0.9	0.74	-0.16	-0.09	-0.51	-0.38	-0.91	-0.23	0.57	-0.35	0.5
Ebitda	-0.36	-0.06	0.42	0.42	-0.71	1.0	1.0	-0.9		-0.74	1.0	0.21	1.0	-0.79	0.16	0.06	0.4	0.22	1.0	0.16	-0.37	0.12	-0.35
Total Operating Expenses	0.51	0.65	0.3	0.3	1.0	-0.74	-0.74	0.87	-0.74		-0.75	-0.74	-0.76	0.74	-0.23	0.07	-0.46	-0.37	-0.75	-0.14	0.83	-0.68	0.73
Income Before Tax	-0.38	-0.1	0.4	0.4	-0.72	1.0	1.0	-0.9	1.0	-0.75		0.24	1.0	-0.81	0.17	0.06	0.41	0.23	1.0	0.15	-0.4	0.15	-0.38
Total Other Income Expense Net	-0.6	-0.96	-0.69	-0.69	-0.76	0.21	0.21	-0.43	0.21	-0.74	0.24		0.25	-0.56	0.36	-0.24	0.18	0.18	0.23	-0.03	-0.97	0.98	-0.93
Net Income	-0.39	-0.11	0.39	0.4	-0.73	1.0	1.0	-0.9	1.0	-0.76	1.0	0.25		-0.81	0.18	0.05	0.4	0.22	1.0	0.15	-0.41	0.16	-0.4
Income Tax Expense	0.71	0.44	-0.13	-0.13	0.73	-0.8	-0.8	0.74	-0.79	0.74	-0.81	-0.56	-0.81		-0.41	0.13	-0.22	-0.05	-0.8	0.0	0.71	-0.5	0.68
Cost Of Revenue	-0.36	-0.32	-0.08	-0.08	-0.23	0.17	0.16	-0.16	0.16	-0.23	0.17	0.36	0.18	-0.41		-0.31	-0.29	-0.35	0.17	-0.54	-0.42	0.33	-0.4
Selling General Administrative	-0.02	0.19	0.19	0.19	0.08	0.07	0.06	-0.09	0.06	0.07	0.06	-0.24	0.05	0.13	-0.31		0.51	0.56	0.06	0.14	0.19	-0.21	0.17
Minority Interest	-0.15	-0.23	-0.04	-0.04	-0.45	0.41	0.4	-0.51	0.4	-0.46	0.41	0.18	0.4	-0.22	-0.29	0.51		0.97	0.41	0.2	-0.27	0.21	-0.25
Selling And Marketing Expenses	-0.08	-0.25	-0.18	-0.18	-0.37	0.22	0.22	-0.38	0.22	-0.37	0.23	0.18	0.22	-0.05	-0.35	0.56	0.97		0.23	0.24	-0.22	0.21	-0.19
Net Income From Continuing Ops	-0.38	-0.09	0.4	0.4	-0.72	1.0	1.0	-0.91	1.0	-0.75	1.0	0.23	1.0	-0.8	0.17	0.06	0.41	0.23		0.16	-0.39	0.14	-0.37
Non Operating Income Net Other	0.05	0.14	0.02	0.02	-0.14	0.15	0.16	-0.23	0.16	-0.14	0.15	-0.03	0.15	0.0	-0.54	0.14	0.2	0.24	0.16		0.07	-0.13	0.14
Interest Income	0.72	0.93	0.58	0.58	0.84	-0.37	-0.37	0.57	-0.37	0.83	-0.4	-0.97	-0.41	0.71	-0.42	0.19	-0.27	-0.22	-0.39	0.07		-0.94	0.93
Net Interest Income	-0.56	-0.99	-0.74	-0.74	-0.71	0.12	0.12	-0.35	0.12	-0.68	0.15	0.98	0.16	-0.5	0.33	-0.21	0.21	0.21	0.14	-0.13	-0.94		-0.93
Reconciled Depreciation	0.6	0.91	0.47	0.47	0.74	-0.36	-0.36	0.5	-0.35	0.73	-0.38	-0.93	-0.4	0.68	-0.4	0.17	-0.25	-0.19	-0.37	0.14	0.93	-0.93

Click cells to compare fundamentals

TG Therapeutics Account Relationship Matchups

TG Therapeutics income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	1.5M	374K	494K	515K	423K	444.2K
Interest Expense	5.3M	6.3M	5.6M	10.2M	12.6M	13.2M
Gross Profit	(130K)	(222K)	5.9M	2.5M	219.1M	230.1M
Other Operating Expenses	169.2M	273.7M	351.5M	195.6M	213.0M	223.7M
Operating Income	(169.1M)	(273.6M)	(344.8M)	(192.8M)	20.6M	21.7M
Ebit	(169.1M)	(273.1M)	(342.5M)	(188.1M)	20.6M	21.7M
Research Development	148.4M	151.9M	198.5M	112.1M	76.2M	45.7M
Ebitda	(167.6M)	(272.7M)	(342.0M)	(187.6M)	21.1M	22.1M
Total Operating Expenses	169.2M	273.7M	350.7M	195.4M	198.5M	208.4M
Income Before Tax	(172.9M)	(279.4M)	(348.1M)	(198.3M)	13.1M	13.7M
Total Other Income Expense Net	(3.8M)	(5.8M)	(3.3M)	(5.5M)	(7.6M)	(7.2M)
Net Income	(179.3M)	(285.9M)	(355.6M)	(203.8M)	12.7M	13.3M
Income Tax Expense	6.5M	6.5M	7.5M	5.5M	390K	370.5K
Cost Of Revenue	282K	374K	790K	265K	14.6M	22.0M
Selling General Administrative	20.8M	121.8M	152.1M	83.2M	135.7M	142.5M
Net Income Applicable To Common Shares	(172.9M)	(279.4M)	(348.1M)	(182.6M)	(164.4M)	(172.6M)
Net Income From Continuing Ops	(172.9M)	(279.4M)	(348.1M)	(182.6M)	12.7M	13.3M
Non Operating Income Net Other	918K	1.5M	542K	2.3M	2.1M	1.1M
Net Interest Income	(5.3M)	(6.3M)	(5.6M)	(10.2M)	(12.6M)	(12.0M)
Reconciled Depreciation	88K	282K	374K	515K	423K	321.6K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

TITAN	Titan Company Limited
U	Unity Software
PAYC	Paycom Soft

Additional Tools for TGTX Stock Analysis

When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

TGTX Historical Income Statement

About TGTX Income Statement Analysis

TG Therapeutics Income Statement Chart

Depreciation And Amortization

Other Operating Expenses

Total Operating Expenses

TG Therapeutics income statement Correlations

TG Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

TG Therapeutics income statement Accounts

Also Currently Popular

Additional Tools for TGTX Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Gross Profit	+ 1.0	Total Revenue
Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebit	+ 1.0	Operating Income
Ebitda	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Operating Income
Net Income	+ 1.0	Operating Income

Net Interest Income	- 0.99	Interest Expense
Interest Income	- 0.97	Total Other Income Expense Net
Total Other Income Expense Net	- 0.96	Interest Expense
Net Interest Income	- 0.94	Interest Income
Reconciled Depreciation	- 0.93	Net Interest Income
Reconciled Depreciation	- 0.93	Total Other Income Expense Net